Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 25

    1.

    Rapid cutaneous dissemination of persistently agminated lymphomatoid papulosis in a 9-year-old boy.

    Chan DV, Staidle J, Tamburro J, Mostow E.

    Arch Dermatol. 2011 Nov;147(11):1340-2. No abstract available.

    PMID:
    22106136
    [PubMed - indexed for MEDLINE]
    2.

    Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

    Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, Hummel M, Loeffler M, Pellissery S, Woessmann W, Schwänen C, Trümper L, Wessendorf S, Spang R, Hasenclever D, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe.

    Blood. 2012 Feb 23;119(8):1882-7. Epub 2012 Jan 11.

    PMID:
    22238326
    [PubMed - indexed for MEDLINE]
    3.

    Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.

    Carlring J, Szabo MJ, Dickinson R, De Leenheer E, Heath AW.

    Blood. 2012 Mar 1;119(9):2056-65. Epub 2012 Jan 10.

    PMID:
    22234700
    [PubMed - indexed for MEDLINE]
    4.

    T-cell immunity to Kaposi sarcoma-associated herpesvirus: recognition of primary effusion lymphoma by LANA-specific CD4+ T cells.

    Sabbah S, Jagne YJ, Zuo J, de Silva T, Ahasan MM, Brander C, Rowland-Jones S, Flanagan KL, Hislop AD.

    Blood. 2012 Mar 1;119(9):2083-92. Epub 2012 Jan 10.

    PMID:
    22234686
    [PubMed - indexed for MEDLINE]
    5.

    Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

    Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U.

    Blood. 2012 Mar 1;119(9):2066-73. Epub 2012 Jan 10.

    PMID:
    22234681
    [PubMed - indexed for MEDLINE]
    6.

    Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

    LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW.

    Blood. 2012 Mar 1;119(9):2093-9. Epub 2012 Jan 10.

    PMID:
    22234679
    [PubMed - indexed for MEDLINE]
    7.

    Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.

    Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L.

    Blood. 2012 Mar 8;119(10):2228-33. Epub 2012 Jan 5.

    PMID:
    22223822
    [PubMed - indexed for MEDLINE]
    8.

    Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

    Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH.

    Blood. 2011 Nov 3;118(18):4882-9. Epub 2011 Jul 1.

    PMID:
    21725056
    [PubMed - indexed for MEDLINE]
    9.

    Burkitt lymphoma and the discovery of Epstein-Barr virus.

    Epstein A.

    Br J Haematol. 2012 Mar;156(6):777-9. doi: 10.1111/j.1365-2141.2011.09008.x. Epub 2012 Jan 11.

    PMID:
    22233499
    [PubMed - indexed for MEDLINE]
    10.

    The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma.

    Mitrovic Z, Bast M, Bierman PJ, Bociek RG, Vose JM, Chan WC, Armitage JO.

    Br J Haematol. 2012 May;157(3):401-3. doi: 10.1111/j.1365-2141.2011.08998.x. Epub 2012 Jan 9. No abstract available.

    PMID:
    22224728
    [PubMed - indexed for MEDLINE]
    11.

    Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis.

    Greaves P, Wilson A, Matthews J, Brown DL, Auer R, Montoto S, Lister TA, Gribben JG.

    Br J Haematol. 2012 Apr;157(2):201-4. doi: 10.1111/j.1365-2141.2011.08993.x. Epub 2012 Jan 9.

    PMID:
    22224653
    [PubMed - indexed for MEDLINE]
    12.

    Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.

    Wondergem MJ, Zijlstra JM, de Rooij M, Visser OJ, Huijgens PC, Zweegman S.

    Br J Haematol. 2012 May;157(3):395-7. doi: 10.1111/j.1365-2141.2011.08991.x. Epub 2012 Jan 9. No abstract available.

    PMID:
    22224561
    [PubMed - indexed for MEDLINE]
    13.

    Neurolymphomatosis in a patient with lymphoblastic lymphoma.

    Wan MY, Ardeshna KM, Bomanji J.

    Br J Haematol. 2012 Mar;156(6):691. doi: 10.1111/j.1365-2141.2011.09002.x. Epub 2012 Jan 6. No abstract available.

    PMID:
    22221268
    [PubMed - indexed for MEDLINE]
    14.

    Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

    Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM.

    Cancer. 2011 Nov 15;117(22):5074-84. doi: 10.1002/cncr.26182. Epub 2011 May 12.

    PMID:
    21567384
    [PubMed - indexed for MEDLINE]
    15.

    Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.

    Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, Levy R.

    Cancer Res. 2012 Mar 1;72(5):1239-47. Epub 2012 Jan 9.

    PMID:
    22232735
    [PubMed - indexed for MEDLINE]
    16.

    Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications.

    Papathomas TG, Venizelos I, Dunphy CH, Said JW, Wang ML, Campo E, Swerdlow SH, Chan JC, Bueso-Ramos CE, Weisenburger DD, Medeiros LJ, Young KH.

    Hum Pathol. 2012 Apr;43(4):467-80. Epub 2012 Jan 4. Review.

    PMID:
    22221705
    [PubMed - indexed for MEDLINE]
    17.

    Revisiting low-dose total skin electron beam therapy in mycosis fungoides.

    Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R.

    Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e651-7. Epub 2011 Apr 12.

    PMID:
    21489711
    [PubMed - indexed for MEDLINE]
    18.

    Primary cutaneous aggressive epidermotropic CD8(+) T-cell lymphoma: Proposed diagnostic criteria and therapeutic evaluation.

    Nofal A, Abdel-Mawla MY, Assaf M, Salah E.

    J Am Acad Dermatol. 2012 Jan 6. [Epub ahead of print]

    PMID:
    22226429
    [PubMed - as supplied by publisher]
    19.

    Severe anemia during rituximab maintenance therapy for follicular lymphoma.

    Liapis K, Harhalakis N, Stefanou G, Apostolidis J.

    J Clin Oncol. 2012 Mar 10;30(8):e95-6. Epub 2012 Jan 9. No abstract available.

    PMID:
    22231048
    [PubMed - indexed for MEDLINE]
    20.

    Non-uremic calcific arteriolopathy (calciphylaxis) in relapsed/refractory Hodgkin's lymphoma: a previously unreported association.

    Sibai H, Ishak RS, Halawi R, Otrock ZK, Salman S, Abu-Alfa A, Kharfan-Dabaja MA.

    J Clin Oncol. 2012 Mar 1;30(7):e88-90. Epub 2012 Jan 9. No abstract available.

    PMID:
    22231039
    [PubMed - in process]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk